We take a closer look at ImmuPharma, the developer of a breakthrough drug for lupus
06.42 Fri 06 Dec 2019
MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering
MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow...
Open Orphan (ORPH) is targeting rapid scale-up and profitability in the dynamic...
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.